4.25
price down icon0.00%   -0.000100
after-market After Hours: 4.25
loading
Genfit Adr stock is traded at $4.25, with a volume of 732. It is down -0.00% in the last 24 hours and up +0.05% over the past month. Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.
See More
Previous Close:
$4.2501
Open:
$4.1872
24h Volume:
732
Relative Volume:
0.15
Market Cap:
$212.51M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-5.7894
EPS:
-0.7341
Net Cash Flow:
-
1W Performance:
+5.46%
1M Performance:
+0.05%
6M Performance:
+25.37%
1Y Performance:
-29.87%
1-Day Range:
Value
$4.1872
$4.27
1-Week Range:
Value
$3.855
$4.49
52-Week Range:
Value
$2.55
$6.4229

Genfit Adr Stock (GNFT) Company Profile

Name
Name
Genfit Adr
Name
Phone
-
Name
Address
-
Name
Employee
125
Name
Twitter
@genfit_pharma
Name
Next Earnings Date
2025-09-22
Name
Latest SEC Filings
Name
GNFT's Discussions on Twitter

Compare GNFT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
GNFT
Genfit Adr
4.25 212.52M 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
407.37 104.55B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
464.95 60.36B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
557.73 59.84B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
799.56 49.07B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
327.03 35.16B 4.56B -176.77M 225.30M -1.7177

Genfit Adr Stock (GNFT) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-19-25 Resumed H.C. Wainwright Buy
Dec-20-21 Upgrade H.C. Wainwright Neutral → Buy
Jul-23-20 Upgrade Stifel Hold → Buy
Jun-25-20 Initiated BofA/Merrill Underperform
May-13-20 Downgrade Kepler Buy → Reduce
May-12-20 Downgrade Barclays Overweight → Equal Weight
May-12-20 Downgrade H.C. Wainwright Buy → Neutral
Oct-29-19 Reiterated B. Riley FBR Buy
Jun-25-19 Initiated Stifel Hold
Apr-24-19 Initiated SVB Leerink Outperform
Apr-22-19 Initiated Barclays Overweight
View All

Genfit Adr Stock (GNFT) Latest News

pulisher
Sep 29, 2025

European ADRs Start The Week With Small Gains Stateside - Finimize

Sep 29, 2025
pulisher
Sep 27, 2025

FY2025 Earnings Estimate for GENFIT Issued By HC Wainwright - Defense World

Sep 27, 2025
pulisher
Sep 26, 2025

FY2025 EPS Estimates for GENFIT Lifted by Leerink Partnrs - Defense World

Sep 26, 2025
pulisher
Sep 26, 2025

HC Wainwright Has Pessimistic View of GENFIT FY2025 Earnings - MarketBeat

Sep 26, 2025
pulisher
Sep 25, 2025

GENFIT (NASDAQ:GNFT) Price Target Lowered to $7.00 at HC Wainwright - Defense World

Sep 25, 2025
pulisher
Sep 24, 2025

HC Wainwright Has Lowered Expectations for GENFIT (NASDAQ:GNFT) Stock Price - MarketBeat

Sep 24, 2025
pulisher
Sep 11, 2025

European ADRs Dip Slightly As Biotech Stocks Jump And Drop - Finimize

Sep 11, 2025
pulisher
Aug 20, 2025

GENFIT (NASDAQ:GNFT) Coverage Initiated by Analysts at HC Wainwright - Defense World

Aug 20, 2025
pulisher
Aug 15, 2025

European Biopharma ADRs: A Strategic Play in a Volatile Market - AInvest

Aug 15, 2025
pulisher
Jul 10, 2025

GENFIT (NASDAQ:GNFT) Shares Up 0.7% – Time to Buy? - Defense World

Jul 10, 2025
pulisher
Jun 30, 2025

European ADRs: Navigating Sectoral Divergence in a Volatile Market - AInvest

Jun 30, 2025
pulisher
Jun 27, 2025

European Biopharma Leads Gains In ADR Market Surge - Finimize

Jun 27, 2025
pulisher
Jun 27, 2025

European Biotech ADRs Lead the Charge: A Sector on the Verge of Breakthrough Growth - AInvest

Jun 27, 2025
pulisher
May 31, 2025

European ADRs Show Strength With Genfit And Novo Nordisk Leading Gains - Finimize

May 31, 2025
pulisher
May 22, 2025

European ADRs Show Optimism As Genfit Leads Gains - Finimize

May 22, 2025
pulisher
May 07, 2025

European ADRs See Mixed Results With Modest Gains - Finimize

May 07, 2025
pulisher
Apr 11, 2025

European Equities Traded in the US as American Depositary Receipts Higher in Friday Trading - TradingView

Apr 11, 2025
pulisher
Apr 09, 2025

European ADRs Climb As Biopharmaceuticals Lead The Charge - Finimize

Apr 09, 2025
pulisher
Apr 08, 2025

European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading - TradingView

Apr 08, 2025
pulisher
Apr 03, 2025

European Equities Traded in the US as American Depositary Receipts Fall in Thursday Trading - TradingView

Apr 03, 2025
pulisher
Apr 01, 2025

European Equities Traded in the US as American Depositary Receipts Tread Water in Tuesday Trading - TradingView

Apr 01, 2025
pulisher
Mar 27, 2025

European Equities Traded in the US as American Depositary Receipts Edge Higher in Thursday Trading - TradingView

Mar 27, 2025
pulisher
Mar 26, 2025

European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading - TradingView

Mar 26, 2025
pulisher
Mar 24, 2025

European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading - TradingView

Mar 24, 2025
pulisher
Mar 14, 2025

European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Down for Week - TradingView

Mar 14, 2025
pulisher
Mar 03, 2025

European Equities Traded in the US as American Depositary Receipts Surge Higher in Monday Trading - TradingView

Mar 03, 2025
pulisher
Feb 28, 2025

European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Remain Flat for Week - TradingView

Feb 28, 2025
pulisher
Jun 10, 2024

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis - GlobeNewswire

Jun 10, 2024
pulisher
Dec 07, 2023

Ipsen confirms U.S. FDA grants priority review for New Drug - GlobeNewswire

Dec 07, 2023
pulisher
Nov 13, 2023

Results from Ipsen’s ELATIVE® pivotal Phase III trial of - GlobeNewswire

Nov 13, 2023
pulisher
Jun 30, 2023

Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease - Ipsen

Jun 30, 2023
pulisher
Dec 17, 2021

Ipsen and GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor, a Phase III Asset Evaluated in Primary Biliary Cholangitis, as Part of a Long-Term Global Partnership - Business Wire

Dec 17, 2021

Genfit Adr Stock (GNFT) Financials Data

There is no financial data for Genfit Adr (GNFT). Check out other stocks for more information.

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$84.73
price up icon 1.11%
$22.93
price up icon 7.40%
$32.68
price up icon 2.73%
$102.30
price up icon 0.24%
$163.94
price up icon 0.99%
biotechnology ONC
$327.03
price up icon 2.16%
Cap:     |  Volume (24h):